Published on April 3, 2013 at 8:12 AM
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Japanese Patent Office. The patent, titled "Methods and Compositions for Oral Administrations of Proteins," covers a core concept of the company's technology. The patent has also been approved in Israel and Australia. Oramed's portfolio now consists of seven issued patents and 28 patents pending.
According to a report by the European Federation of Pharmaceutical Industries and Associations, Japan constitutes 12% of the global sales of new medicines launched in the period from 2006 to 2010.
Nadav Kidron , CEO of Oramed, commented, "We are very excited to add the Japanese patent to our international portfolio. The Japanese patent approval represents a great success in further establishing the global standing of Oramed's innovative oral delivery technology."
SOURCE Oramed Pharmaceuticals Inc.